FDA approves once-nightly Lumryz for narcolepsy

Lumryz (sodium oxybate for extended-release oral suspension) is the first once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy. Approval was based on data from the phase 3 REST-ON study involving 212 patients. The most common adverse reactions reported during treatment include nausea, dizziness, enuresis, headache, and vomiting.